Aspirin as antiplatelet agent in diabetes. PROS-

European Journal of Internal Medicine

Volumn 21, Issue 3, 2010, Pages 149-153

  Davi G ^a   Santilli, F ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CYCLOOXYGENASE 1; INSULIN; PRASUGREL; THROMBOXANE;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SENSITIVITY; DRUG TREATMENT FAILURE; EVIDENCE BASED MEDICINE; HEART INFARCTION; HUMAN; LOW DRUG DOSE; PRIMARY PREVENTION; RECOMMENDED DRUG DOSE; RISK REDUCTION; STROKE; THROMBOEMBOLISM;

EID: 77952290056     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2010.03.008     Document Type: Note

References (50)

1. Luscher T.F., Creager M.A., Beckman J.A., and Cosentino F. Diabetes and vascular disease: pathophysiology, clinical consequences and medical therapy. Circulation 108 (2003) 1655-1661
2. Schramm T.K., Gislason G.H., Køber L., Rasmussen S., Rasmussen J.N., Abildstrøm S.Z., et al. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation 117 (2008) 1945-1954
3. Davì G., Gresele P., Violi F., Basili S., Catalano M., Giammarresi C., et al. Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease. Circulation 96 (1997) 69-75
4. Ferroni P., Basili S., Falco A., and Davì G. Platelet activation in type 2 diabetes mellitus. J Thromb Haemost 2 (2004) 1282-1291
5. Davì G., Ciabattoni G., Consoli A., Mezzetti A., Falco A., Santarone S., et al. In vivo formation of 8-iso-prostaglandin F2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 99 (1999) 224-229
6. Davì G., Catalano I., Averna M., Notarbartolo A., Strano A., Ciabattoni G., et al. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 322 (1990) 1769-1774
7. Santilli F., Davì G., Consoli A., Cipollone F., Mezzetti A., Falco A., et al. Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus. J Am Coll Cardiol 47 (2006) 391-397
8. Davì G., Chiarelli F., Santilli F., Pomilio M., Vigneri S., Falco A., et al. Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: role of interleukin-6 and disease duration. Circulation 107 (2003) 3199-3203
9. Santilli F., Formoso G., Sbraccia P., Averna M., Miccoli R., Di Fulvio P., et al. Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus. J Thromb Haemost (2010 Jan 17)
10. Gresele P., Guglielmini G., De Angelis M., Ciferri S., Ciofetta M., Falcinelli E., et al. Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus. J Am Coll Cardiol 41 (2003) 1013-1020
11. Santilli F., Vazzana N., Bucciarelli L.G., and Davì G. Soluble forms of RAGE in human diseases: clinical and therapeutical implications. Curr Med Chem 16 (2009) 940-952
12. Davì G., Falco A., and Patrono C. Lipid peroxidation in diabetes mellitus. Antioxid Redox Signal 7 (2005) 256-268
13. Davì G., Falco A., and Patrono C. Determinants of F2-isoprostane biosynthesis and inhibition in man. Chem Phys Lipids 128 (2004) 149-163
14. Davì G., Guagnano M.T., Ciabattoni A., Basili S., Falco A., Marinopiccoli M., et al. Platelet activation in obese women: role of inflammation and oxidant stress. JAMA 288 (2002) 2008-2014
15. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 330 (1994) 1287-1294
16. Antithrombotic Trialists' (ATT) Collaboration, Baigent C., Blackwell L., Collins R., Emberson J., Godwin J., et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373 (2009) 1849-1860
17. Santilli F., Romano M., Recchiuti A., Dragani A., Falco A., Lessiani G., et al. Circulating endothelial progenitor cells and residual in vivo thromboxane biosynthesis in low-dose aspirin-treated polycythemia vera patients. Blood 112 (2008) 1085-1090
18. Dragani A., Pascale S., Recchiuti A., Mattoscio D., Lattanzio S., Petrucci G., et al. The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy. Blood 115 (2010) 1054-1061
19. American Diabetes Association Clinical Practice Recommendations. Diabetes Care 33 (2010) S1-S100
20. Investigators E.T.D.R.S. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. JAMA 268 (1992) 1292-1300
21. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308 (1994) 81-106
22. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ 324 (2002) 71-86
23. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians'Health Study. N Engl J Med 321 (1989) 129-135
24. Hansson L., Zanchetti A., Carruthers S.G., Dahlof B., Elmfeldt D., Julius S., et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial: HOT Study Group. Lancet 351 (1998) 1755-1762
25. Sacco M., Pellegrini F., Roncaglioni M.C., Avanzini F., and Tognoni G. Nicolucci A; PPP Collaborative Group. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care 26 (2003) 3264-3272
26. De Berardis G., Sacco M., Strippoli G.F., Pellegrini F., Graziano G., Tognoni G., et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ 339 (2009) b4531
27. Belch J., MacCuish A., Campbell I., Cobbe S., Taylor R., Prescott R., et al. Prevention of Progression of Arterial Disease and Diabetes Study Group; Diabetes Registry Group; Royal College of Physicians Edinburgh. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 337 (2008) a1840
28. Ogawa H., Nakayama M., Morimoto T., Uemura S., Kanauchi M., Doi N., et al. Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 300 (2008) 2134-2141
29. Davì G., and Patrono C. Platelet activation and atherothrombosis. N Engl J Med 357 (2007) 2482-2494
30. Lordkipanidzé M., Pharand C., Schampaert E., Turgeon J., Palisaitis D.A., and Diodati J.G. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 28 (2007) 1702-1708
31. Snoep J.D., Hovens M.M.C., Eikenboom J.C.J., van der Bom J.G., and Huisman M.V. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events. A systematic review and meta-analysis. Arch Intern Med 167 (2007) 1593-1599
32. Krasopoulos G., Brister S.J., Beattie W.S., and Buchanan M.R. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 336 (2008) 195-198
33. Santilli F., Rocca B., De Cristofaro R., Lattanzio S., Pietrangelo L., Habib A., et al. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance". J Am Coll Cardiol 53 (2009) 667-677
34. Price H.C., and Holman R.R. Primary prevention of cardiovascular events in diabetes: is there a role for aspirin?. Nat Clin Pract Cardiovasc Med 6 (2009) 168-169
35. Ajjan R., Storey R.F., and Grant P.J. Aspirin resistance and diabetes mellitus. Diabetologia 51 (2008) 385-390
36. Watala C., Pluta J., Golanski J., Rozalski M., Czyz M., Trojanowski Z., et al. Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin. J Mol Med 83 (2005) 148-158
37. Pulcinelli F.M., Biasucci L.M., Riondino S., Giubilato S., Leo A., Di Renzo L., et al. COX-1 sensitivity and thromboxane A2 production in type 1 and type 2 diabetic patients under chronic aspirin treatment. Eur Heart J 30 (2009) 1279-1286
38. DiChiara J., Bliden K.P., Tantry U.S., Hamed M.S., Antonino M.J., Suarez T.A., et al. The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. Diabetes 56 (2007) 3014-3019
39. Evangelista V., de Berardis G., Totani L., Avanzini F., Giorda C.B., Brero L., et al. Persistent platelet activation in patients with type 2 diabetes treated with low doses of aspirin. J Thromb Haemost 5 (2007) 2197-2203
40. Bhatt D.L., Fox K.A., Hacke W., Berger P.B., Black H.R., Boden W.E., et al. CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354 (2006) 1706-1717
41. Dasgupta A., Steinhubl S.R., Bhatt D.L., Berger P.B., Shao M., Mak K.H., et al. CHARISMA Investigators. Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial). Am J Cardiol 103 (2009) 1359-1363
42. Natarajan A., Marshall S.M., Worthley S.G., Badimon J.J., and Zaman A.G. The presence of coronary artery disease increases platelet-dependent thrombosis in patients with type 2 diabetes mellitus. J Thromb Haemost 6 (2008) 2210-2213
43. Bhatt D.L., Marso S.P., Hirsch A.T., Ringleb P.A., Hacke W., and Topol E.J. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 90 (2002) 625-628
44. Ferreira I.A., Mocking A.I., Feijge M.A., Gorter G., Van Haeften T.W., Heemskerk J.W., et al. Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 26 (2006) 417-422
45. Angiolillo D.J., Shoemaker S.B., Desai B., Yuan H., Charlton R.K., Bernardo E., et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 115 (2007) 708-716
46. Singla A., Antonino M.J., Bliden K.P., Tantry U.S., and Gurbel P.A. The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy. Am Heart J 158 (2009) 784.e1-6
47. Wiviott S.D., Braunwald E., McCabe C.H., Montalescot G., Ruzyllo W., Gottlieb S., et al. TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357 (2007) 2001-2015
48. Fuster V., and Farkouh M.E. Acute coronary syndromes and diabetes mellitus: a winning ticket for prasugrel. Circulation 118 (2008) 1607-1608
49. Rocca B., Secchiero P., Ciabattoni G., Ranelletti F.O., Catani L., Guidotti L., et al. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci U S A 99 (2002) 7634-7639
50. Guthikonda S., Lev E.I., Patel R., DeLao T., Bergeron A.L., Dong J.F., et al. Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. J Thromb Haemost 5 (2007) 490-496